Insider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells 10,000 Shares of Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $5.25, for a total value of $52,500.00. Following the sale, the director now owns 61,156 shares in the company, valued at $321,069. This represents a 14.05 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Rosty Raykov also recently made the following trade(s):

• On Wednesday, March 5th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.79, for a total transaction of $67,900.00.
• On Wednesday, February 5th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.66, for a total transaction of $66,600.00.
• On Monday, January 6th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.08, for a total transaction of $60,800.00.

Fennec Pharmaceuticals Stock Performance

Shares of NASDAQ:FENC opened at $5.25 on Monday. Fennec Pharmaceuticals Inc has a 1-year low of $3.96 and a 1-year high of $11.11. The company’s fifty day moving average is $6.51 and its two-hundred day moving average is $5.73. The stock has a market capitalization of $144.84 million, a price-to-earnings ratio of -52.49 and a beta of 0.32.

Analyst Ratings Changes

Several brokerages have recently commented on FENC. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a research report on Tuesday, March 11th. Wedbush reaffirmed an “outperform” rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a report on Monday, March 10th.

Hedge Funds Weigh In On Fennec Pharmaceuticals

Large investors have recently bought and sold shares of the business. Barclays PLC grew its holdings in shares of Fennec Pharmaceuticals by 274.3% during the third quarter. Barclays PLC now owns 31,319 shares of the company’s stock valued at $157,000 after purchasing an additional 22,951 shares during the last quarter. State Street Corp grew its stake in Fennec Pharmaceuticals by 2.2% during the 3rd quarter. State Street Corp now owns 328,259 shares of the company’s stock worth $1,641,000 after buying an additional 7,053 shares during the last quarter. Rhumbline Advisers increased its position in Fennec Pharmaceuticals by 12.9% in the fourth quarter. Rhumbline Advisers now owns 34,299 shares of the company’s stock worth $217,000 after buying an additional 3,911 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Fennec Pharmaceuticals by 10.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 61,146 shares of the company’s stock valued at $386,000 after buying an additional 5,694 shares during the last quarter. Finally, Franklin Resources Inc. boosted its holdings in shares of Fennec Pharmaceuticals by 18.7% during the third quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock valued at $74,000 after acquiring an additional 2,330 shares during the period. Institutional investors own 55.51% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.